Research presented at the American Heart Association's Scientific Sessions 2025 suggests that adults with atrial fibrillation and obesity may have fewer AFib episodes after ablation when taking metformin. The study found that metformin users were more likely to remain AFib-free for a year, indicating promising results in reducing irregular heart rhythms. Future studies may further explore metformin's effectiveness in treating AFib in overweight individuals compared to other diabetes medications.
